Clarient is a provider of comprehensive cancer diagnostic testing to hospitals, physicians and the pharmaceutical industry. The company is dedicated to providing clarity to complex problems by using multiple technologies to help clients diagnose cancer cases.
Missing: Clarient's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Clarient's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Clarient
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Clarient is included in 2 Expert Collections, including Medical Devices.
Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.
Clarient has filed 1 patent.
Molecular biology, Polymer chemistry, Protein methods, Immunologic tests, Biotechnology
Molecular biology, Polymer chemistry, Protein methods, Immunologic tests, Biotechnology
Latest Clarient News
Dec 13, 2018
| Source: NeoGenomics, Inc. FT. MYERS, Fla., Dec. 13, 2018 (GLOBE NEWSWIRE) -- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today announced the appointment of Lawrence M. Weiss, M.D. Dr. Weiss joined NeoGenomics and has served as Medical Director and Laboratory Director for NeoGenomics Laboratories since joining NeoGenomics as part of the Clarient acquisition in 2015. “We are delighted to announce Dr. Weiss as our Chief Scientific Officer,” said Douglas M. VanOort, NeoGenomics’ Chairman and CEO. “Larry is a highly-regarded thought-leader in the oncology and pathology community, with years of medical and scientific leadership experience at NeoGenomics and other organizations. As Chief Scientific Officer, Dr. Weiss is responsible for driving NeoGenomics scientific innovation initiatives and advancing our reputation in the oncology diagnostics community.” Dr. Weiss holds a B.S. from the University of Maryland at College Park, where he graduated as Class Valedictorian, Summa cum Laude, and Phi Sigma, and an M.D. from the University of Maryland School of Medicine where he received the Faculty Gold Medal for Outstanding Qualifications for the Practice of Medicine, the university’s highest award, the Francis Donaldson Award for Highest Achievement in Pathology, and graduated with the additional honors of Summa cum Laude and Alpha Omega Alpha. He has won the Arthur Purdy Stout Award, the Benjamin Castleman Award, and USCAP’s Young Investigator Award (now called Ramzi Cotran Award). Prior to joining NeoGenomics, Dr. Weiss served as Laboratory Director for Clarient Diagnostic Services and as Chairman of the Department of Pathology and Director of Laboratories for City of Hope National Medical Center. Dr. Weiss is currently Visiting Professor in the Department of Pathology and Medicine for the University of California at Irvine and is Chairman Emeritus of Pathology at City of Hope National Medical Center. About NeoGenomics, Inc. NeoGenomics, Inc. specializes in cancer genetics testing and information services. The Company provides one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The Company’s Pharma Services division serves pharmaceutical clients in clinical trials and drug development. Headquartered in Fort Myers, FL, NeoGenomics operates CLIA certified laboratories in Aliso Viejo and Fresno, California; Tampa and Fort Myers, Florida; Houston, Texas; Nashville, Tennessee and Rolle, Switzerland. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States. For additional information about NeoGenomics, visit http://neogenomics.com/ . Forward Looking Statements Certain information contained in this press release constitutes forward-looking statements for purposes of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995, including the estimated effect of the Genoptix acquisition on our financial statements. These forward looking statements involve a number of risks and uncertainties that could cause actual future results to differ materially from those anticipated in the forward-looking statements as the result of the Company’s ability to continue gaining new customers, offer new types of tests, and otherwise implement its business plan, as well as additional factors discussed under the heading “Risk Factors” and elsewhere in the Company’s Quarterly Report on Form 10-K filed with the SEC on March 13, 2018. As a result, this press release should be read in conjunction with the Company's periodic filings with the SEC. In addition, it is the Company’s practice to make information about the Company available by posting copies of its Company Overview Presentation from time to time on the Investor Relations section of its website at http://ir.neogenomics.com/ . Forward-looking statements represent the Company’s estimates only as of the date such statements are made (unless another date is indicated) and should not be relied upon as representing the Company’s estimates as of any subsequent date. While the Company may elect to update forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, even if its estimates change. For further information, please contact: NeoGenomics, Inc.
Clarient Frequently Asked Questions (FAQ)
When was Clarient founded?
Clarient was founded in 1993.
Where is Clarient's headquarters?
Clarient's headquarters is located at 31 Columbia, Aliso Viejo.
What is Clarient's latest funding round?
Clarient's latest funding round is Acquired.
How much did Clarient raise?
Clarient raised a total of $65.65M.
Who are the investors of Clarient?
Investors of Clarient include NeoGenomics Laboratories, GE Healthcare, Oak Investment Partners, Safeguard Scientifics, Castle Creek Capital and 26 more.
Who are Clarient's competitors?
Competitors of Clarient include btt, Digirad, Epocal, TruTouch Technologies, Minomic International, Freedom Scientific, Mitomics, CancerGuide Diagnostics, SenoRx, Biopticon and 15 more.
Compare Clarient to Competitors
Mitomics, formerly Genesis Genomics, is developing molecular tests based on the mitochondrial genome in order to improve clinical insight and therapeutic decisions that affect patients worldwide. Leveraging its insights into the role of mitochondrial DNA (mtDNA), the company is developing a portfolio of molecular tests addressing significant unmet needs in oncology, including those related to prostate, breast, lung and skin cancers, and other disease states. The unique structural and functional characteristics of mtDNA make it a highly attractive system for biomarker discovery, early disease detection, monitoring, risk assessment and therapeutic targeting.
Tears For Life, a medical diagnostic equipment company currently developing a non-invasive tear test kit that will be able to screen women for breast cancer using proteins found in their tears.
Lifepoint is a medical technology company developing rapid and cost effective, non-invasive, on-site diagnostic products. The Company has developed and will continue to develop patented, proprietary technologies utilizing saliva as a test specimen to provide blood equivalent diagnostic results without the need for blood or urine.
btt provides non-invasive and continuous wearable technology that tracks human brain temperature through the brain's thermal tunnel. The company was founded in 2006 and is based in Miami, Florida.
Founded in 1998, Investigen, Inc., is an innovator in DNA testing, developing new processes to shorten testing time and reduce the cost of DNA diagnostic testing and detection of microorganisms and genetically modified organisms (GMOs). Investigen's tests have already demonstrated significant value for food quality assurance, health care, environmental safety, and industry.http://www.investigen.comDidier Perez, Phone: 510-964-9700, Email: email@example.com
PointCare Technologies is a medical device company building diagnostic devices
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.